Methinks AI
Marc Subirats has extensive experience in the healthcare and technology industry. Marc is currently a General Partner at Nina Capital, a venture capital firm focused on healthcare and technology. Prior to this role, they served as a Partner at Nina Capital and also held the position of Limited Partner and Operating Partner.
In addition to their role at Nina Capital, Marc Subirats is a Board Director at Zetta Genomics Ltd, a company specializing in genomic data management for precision medicine. Marc also serves as a Board Director at Methinks AI, a startup using machine learning and artificial intelligence to improve outcomes for patients with life-threatening conditions.
Before joining Nina Capital, Marc Subirats was the General Manager of International Business at Teladoc Health. Marc was also the Founder and CEO of Advance Medical, Inc., a global leader in telemedicine and virtual care services that was later acquired by Teladoc.
Marc Subirats began their career in corporate strategy at Philips.
Marc Subirats attended IESE Business School from 1997 to 1999, where they earned a Master of Business Administration (MBA) degree with a focus on Business and Economics. In 1998, they participated in an exchange program at China Europe International Business School (CEIBS) as part of their MBA studies. Prior to their time at IESE, Marc Subirats completed a degree in Economics at Universitat Autònoma de Barcelona from 1990 to 1995.
This person is not in any teams
Methinks AI
Recent advances in artificial intelligence have made it possible for computers to understand images, sound, text and make decisions, in many cases, better and faster than humans.Methinks uses these new techniques, namely, Google's new deep learning framework, Tensorflow, to analise neuroimaging for diagnosis of brain related diseases.Wefocus on specific pathologies, like acute stroke, to obtain clinical excellence.